News
6d
MedPage Today on MSNLow-Dose Aspirin Reduces Colon Cancer Risk in Patients With Lynch SyndromeBleeding events occurred substantially less often with the lower dose of aspirin, reported John Burn, MD, of Newcastle ...
DALLAS, TX (IANS) – Low-dose acetylsalicylic acid, also known as aspirin, may reduce inflammation among people suffering from sleep loss, according to a new study on June 10.
MINNEAPOLIS — Universal presumption of low-dose aspirin, instead of risk-based screenings, can increase uptake for preeclampsia prevention in underserved populations, according to a speaker at ...
Too many people are missing out on a potentially life-changing opportunity to prevent cancer,” said Sir John Burn.
Bayer submits New Drug Application (NDA) for gadoquatrane: The investigational macrocyclic gadolinium-based contrast agent is designed for contrast-enhanced MRI of the central nervous system and other ...
High-dose aspirin (HDA) is used with intravenous immunoglobulin (IVIg) in Kawasaki disease (KD). Practice regarding HDA varies, and it is unclear whether HDA duration affects the long-term course ...
Based on these new findings, the National Institute of Health and Care Excellence recommends people with Lynch syndrome ...
Twenty-five patients were recruited in the study (14 male and 11 female patients). The median number of previous lines was 2 (2-4) with 76% exposed to pazopanib. The 3-month PFR was 56% with a median ...
This cross-sectional substudy of the LoDoCo2 trial investigated if treatment with low-dose colchicine would attenuate coronary inflammation, as evidenced by less attenuation of pericoronary ...
This is a single-arm, Simon 2-stage trial. Patients with synovial sarcomas who had progressed on at least two lines were administered daily regorafenib (80/120 mg alternating once daily per orally).
Cite this: Efficacy of a Low-Dose Omeprazole-Based Triple-Therapy Regimen for Helicobacter pylori Eradication Independent of Cytochrome P450 Genotype - Medscape - May 01, 2005.
Solve M.E. Selects Simmaron Research As Recipient of ME/CFS Catalyst Award to Accelerate Low-Dose Rapamycin Trial for ME/CFS, Long COVID, and IACCs By Solve M.E. Jun 17, 2025 Updated Jun 17, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results